1263425-71-3

Upstream product

• 1263425-69-9 tert-butyl 6-chloro-3-iodoimidazo[1,2-b]pyridazin-8-yl-((tetrahydro-2H-pyran-4-yl)methyl)carbamate 
• 1263425-62-2 tert-butyl 6-chloroimidazo[1,2-b]pyridazin-8-yl((tetrahydro-2H-pyran-4-yl)methyl)carbamate 
• 1263425-61-1 6-chloro-N-((tetrahydro-2H-pyran-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine 
• 130290-79-8 4-tetrahydropyranmethylamine 
• 827614-68-6 N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 933034-89-0 8-bromo-6-chloro-imidazo[1,2-b]pyridazine hydrochloride 
• 180516-87-4 4-carboxyphenylboronic acid pinacol ester 

Relevant academic research and scientific papers

FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION

Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR1—, ═N—, —CR7═), (—CR2═, ═N—, ═N—, —CR7═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NRA—, etc.; Z is a group represented by the formula —NR3R4 or a group represented by the formula —OR5; R1 to R3, R6, and R7 each is a hydrogen atom, etc.; R4 and R5 each is an (un)substituted alkyl, etc.; and R8 is an (un)substituted cycloalkyl, etc.